Phase 4
N=62
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Liver Transplantation · Postreperfusion Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT01001403 ↗Enrolled (actual)
62
Serious AEs
0.0%
Results posted
May 2010
Primary outcome: Primary: Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS) — 15; 25 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Nafamostat (Drug); Normal saline (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Seoul National University Hospital
- Primary completion
- Mar 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS) |
15; 25 | — |
Summary
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.
Eligibility Criteria
Inclusion Criteria
- >= 18 year old scheduled to undergo liver transplantation
Exclusion Criteria
- Previous history of pulmonary, cardiovascular, or renal disease
- Previous history of allergic reactions to nafamostat
Data sourced from ClinicalTrials.gov (NCT01001403). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.